Fernanda Manaia Demarqui

Mrs. Fernanda Manaia Demarqui


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Molecules
Verified
Journal Article
Open access
PDF file
RSRaphael Tristão Cruvinel Silva
Raphael Tristão Cruvinel Silva
MICAELA GUIDOTTI TAKEUCHIMICAELA GUIDOTTI TAKEUCHI
MICAELA GUIDOTTI TAKEUCHI
JPJéssica Laura Miranda Peixoto
Jéssica Laura Miranda Peixoto
FDFernanda Manaia Demarqui
Fernanda Manaia Demarqui
AMAnanda Paula Mori
Ananda Paula Mori
WGWendell Guerra
Wendell Guerra
This work describes the preparation, characterization and antimicrobial activity of four palladium(II) complexes, namely, [Pd(meg)(1,10-phen)] 1, [Pd(meg)(PPh3)2] 2, [Pd(og)(1,10-phen)] 3 and [Pd(og)(PPh3)2] 4, where meg = methyl gallate, og = octyl gallate, 1,10-phen = 1,10-phenanthroline and PPh3 = triphenylphosphine. As to the chemical structures, spectral and physicochemical studies of 1–4 indicated that methyl or octyl gallate coordinates a palladium(II) ion through two oxygen atoms upon deprotonation. A chelating bidentate phenanthroline or two triphenylphosphine molecules complete the coordination sphere of palladium(II) ion, depending on the complex. The metal complexes were tested against the Mycobacterium tuberculosis H37Rv strain and 2 exhibited high activity (MIC = 3.28 μg/mL). As to the tests with Campylobacter jejuni, complex 1 showed a significant effect in reducing bacterial population (greater than 7 log CFU) in planktonic forms, as well as in the biomass intensity (IBF: 0.87) when compared to peracetic acid (IBF: 1.11) at a concentration of 400 μg/mL. The effect provided by these complexes has specificity according to the target microorganism and represent a promising alternative for the control of microorganisms of public health importance.

21 April 2023 in ChemMedChem
Verified
Journal Article
Open access
GFGuilherme Fernandes
Guilherme Fernandes
KMKaryn F. Manieri
Karyn F. Manieri
ABAndressa Francielli Bonjorno
Andressa Francielli Bonjorno
DCDebora L. Campos
Debora L. Campos
CRCamila M. Ribeiro
Camila M. Ribeiro
JSJean L. Dos Santos
Jean L. Dos Santos
The emergence of multidrug‐resistant strains of M. tuberculosis has raised concerns due to the greater difficulties in patient treatment and higher mortality rates. Herein, we revisited the 2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazine scaffold and identified potent new carbamate derivatives having MIC90 values of 0.18–1.63 μM against Mtb H37Rv. Compounds 47–49, 51–53, and 55 exhibited remarkable activity against a panel of clinical isolates, displaying MIC90 values below 0.5 μM. In Mtb‐infected macrophages, several compounds demonstrated a 1‐log greater reduction in mycobacterial burden than rifampicin and pretomanid. The compounds tested did not exhibit significant cytotoxicity against three cell lines or any toxicity to Galleria mellonella. Furthermore, the imidazo[2,1‐b][1,3]oxazine derivatives did not show substantial activity against other bacteria or fungi. Finally, molecular docking studies revealed that the new compounds could interact with the deazaflavin‐dependent nitroreductase (Ddn) in a similar manner to pretomanid. Collectively, our findings highlight the chemical universe of imidazo[2,1‐b][1,3]oxazines and their promising potential against MDR‐TB.

26 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DCDébora Leite Campos
Débora Leite Campos
FDFernanda Manaia Demarqui
Fernanda Manaia Demarqui
MSMariana Cristina Solcia
Mariana Cristina Solcia
Paula Carolina de SouzaPaula Carolina de Souza
Paula Carolina de Souza
PMPedro Ivo da Silva Maia
Pedro Ivo da Silva Maia
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan
As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.

20 December 2020
Verified
Book Chapter
Closed access
PDF file
FDFernanda Manaia Demarqui
Fernanda Manaia Demarqui
APAna Carolina Silva Paiva
Ana Carolina Silva Paiva
MSMariana Marchi Santoni
Mariana Marchi Santoni
TWTatiana Faria Watanabe
Tatiana Faria Watanabe
SVSandro Roberto Valentini
Sandro Roberto Valentini
CZCleslei Fernando Zanelli
Cleslei Fernando Zanelli